AUTHORS
Amandeep Salhotra, MD, Dongyun Yang, PhD2, Sally Mokhtari, PhD3, Nelli Bejanyan, MD4, Monzr M. M Al Malki, MD5, Firoozeh Sahebi6, Karamjeet Singh Sandhu, MD7, Ji-Lian Cai, MD, PhD8, Vaibhav Agrawal, MD9, Ahmed Aribi, MD10, Leonardo T Farol11, Nahid Rashid, MD12, Sunmin Park, MD PhD13, Rick Y. Lin, MD14, Haris Ali, MD15, Ibrahim Aldoss, MD16, Salman Otoukesh, MD17, Brian John Ball, MD, MS18, Paul Koller, MD19, Idoroenyi Amanam, MD20, Tamer Othman, MD21, Samer K. Khaled, MD22, Hoda Pourhassan, MD23, Amanda Blackmon, DO24, Pamela S. Becker, MD, PhD25, Vinod Pullarkat, MD26, Andrew Artz, MD,MS27, Eileen Smith, MD28, Guido Marcucci, MD29, Stephen J. Forman, MD30, Anthony Selwyn Stein, MD31, Ryotaro Nakamura, MD32
AFFILIATIONS
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States
3 City of Hope, Duarte, California, United States
4 Moffit Cancer Center, Tampa, Florida, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
11 City of Hope, Duarte, California, United States
12 City of Hope, Duarte, California, United States
13 City of Hope, Duarte, California, United States
14 City of Hope, Duarte, California, United States
15 City of Hope, Duarte, California, United States
16 City of Hope, Duarte, California, United States
17 City of Hope, Duarte, California, United States
18 City of Hope, Duarte, California, United States
19 City of Hope, Duarte, California, United States
20 City of Hope, Duarte, California, United States
21 City of Hope, Duarte, California, United States
22 City of Hope, Duarte, California, United States
23 City of Hope, Duarte, California, United States
24 City of Hope, Duarte, California, United States
25 City of Hope, Duarte, California, United States
26 City of Hope, Duarte, California, United States
27 City of Hope, Duarte, California, United States
28 City of Hope, Duarte, California, United States
29 City of Hope, Duarte, California, United States
30 City of Hope, Duarte, California, United States
31 City of Hope, Duarte, California, United States
32 City of Hope, Duarte, California, United States
ABSTRACT
Somatic mutations in IDH genes are detected in ~20% of patients with AML, with IDH2 mutations (R172, R140) accounting for the majority of cases (15%). Given our prior observation of higher 1-year relapse rate after HCT in patients with IDH mutated AML (PMC9129101), we investigated post-HCT targeted maintenance with enasidenib, an IDH2 inhibitor, to reduce relapse risk in a Phase 1/2 clinical trial (NCT03728335). The pilot portion of this multicenter trial [City of Hope (COH) and Moffitt Cancer Center] established the safety and feasibility of enasidenib maintenance after alloHCT and showed encouraging survival outcomes. Building on these data, the phase 2 portion tested the hypothesis that post-HCT enasidenib maintenance improves leukemia-free survival (LFS) in patients with IDH2-mutated AML. We report results from the completed multicenter Phase 1/2 cohort.
The primary objective of the Phase 2 portion was to evaluate the efficacy of enasidenib as post-HCT maintenance in IDH2-mutated AML, defined by 2-year LFS. Secondary objectives included safety, 1- and 2-years overall survival (OS), chronic graft-vs-host disease (cGVHD), and cGVHD-free and relapse-free survival (CRFS).
Adult alloHCT recipients carrying IDH2-mutated AML were included (n=35; phase 1, n=15; phase 2, n=20; 28 at COH and 7 at Moffitt). Patients were eligible for maintenance therapy irrespective of conditioning regimen if they were in complete remission (CR) at day +30 post-HCT, had ECOG ≤2 and adequate marrow function. Patients with active grade ≥2 acute GVHD were excluded. Enasidenib was given at the safe dose established in the phase 1 portion of the trial (100 mg/day) between days +50 and +120 post-HCT and continued for 2 years in 28-day cycles.
The median age for the whole cohort was 62 years (range 24-80), 54.3% of patients were female, and 89% were non-Hispanic/Latino. Pre-HCT disease status was CR1 in 88.6%, CR2 in 8.6%, and MRD+ in 2.9%. Cytogenetic risk was favorable, intermediate, and adverse in 8.6%, 71.5%, and 17.1%, respectively. Donor types were match unrelated (65.7%), related (20%), or haploidentical (14.3%). Most patients (68%) underwent reduced intensity conditioning, and all received PBSC grafts. Most used GVHD prophylaxis regimens were tacrolimus- (60%) or PTCy- based (20%).
At the data cutoff date of July 2026, 12 patients (Phase 1) had completed the planned 2-year course of enasidenib maintenance while 14 patients (Phase 2) continued enasidenib maintenance as they remained within the planned 2-year treatment period. Reasons for maintenance discontinuation were toxicity (n=1), loss of follow up or withdrawal (n=4), physician discretion (n=3), and disease relapse (n=1). Median follow up duration was 14 months (range 1-24). Cycle delays were recorded in 10 patients (8 in phase 1 n=8; 2 in phase 2), and dose modification were implemented in 7 patients (4 in phase 1 and 3 in phase 2).
All grade adverse effects (AEs) were collected during the first 2 cycles, and grade ≥3 AEs during subsequent cycles. During the first 2 cycles, the most common grade ≥3 AEs were hematologic including: lymphopenia (46%; n=7), anemia (53%; n=8), neutropenia (13%; n=2), and thrombocytopenia (33%; n=5). Non-hematologic AEs included grade 1-2 nausea (60%; n=9), and vomiting/diarrhea (26%; n=4).
The 1- and 2-year OS were both 93%, and LFS was 89% at both time points, reflecting durable disease control with no deaths beyond year 1. NRM remained low at 7% at 1 and 2 years, and relapse was uncommon, with a 1- and 2-year cumulative incidence of relapse of 4%. The cumulative incidence of any cGVHD was 16% at 6 months and 20% at 12 months post-HCT, while moderate-to-severe cGVHD remained low at 3% at both time points. The cumulative incidence of any cGVHD was 16% at 6 months and 20% at 12 months post-HCT, while moderate-to-severe cGVHD remained low at 3% at both time points. CRFS was 81% at 12 months and 65% at 24 months post-HCT corresponding to the low relapse and cGVHD rates.
In conclusion, post-HCT enasidenib maintenance at the phase 1 established dose was safe and feasible, with favorable 2-year LFS. Post-HCT enasidenib was also associated with favorable OS, low NRM, low relapse incidence, low rates of cGVHD, in patients with IDH2-mutated AML. Despite treatment delays and dose modification, discontinuation due to toxicity was uncommon. Our data supports post-HCT enasidenib maintenance as a promising strategy to maintain disease control after alloHCT.
DISCLOSURES
Amandeep Salhotra, MD: Sobi - Research Funding; Incyte - Research Funding; Rigel - Research Funding; Bristol-Myers Squibb - Research Funding; OrcaBio - Research Funding; Jazz Pharma - Research Funding; Pierview - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)